Skip to main content
Delfa

← All trials/NCT02560376

UnknownPhase EARLY_1

68Ga-NOTA-exendin-4 PET/CT for the Localization of Insulinoma and Diagnosis of Nesidioblastosis

Asset

Exenatide

GLP-1 agonist

Listed sites

1

Recruiting sites

1

Estimated enrollment

100

Study population

Oncology

Eligibility highlights

-

Primary endpoint

•Standardized uptake value of 68Ga-NOTA-exendin-4 PET/CT in Diagnosis

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02560376
Org study IDPUMCHNM12
Secondary IDZIAEB000073

Timeline

Milestones

Study first posted2015-09-25estimated
Last update posted2015-09-25estimated
Study start2014-02 (month precision)
Primary completion2016-12estimated (month precision)
Study completion2016-12estimated (month precision)

Assets

Investigational agents

Exenatide

Who this study enrolls

Oncology

Who can enroll

Minimum age6 Years
Maximum age70 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Patients with hypoglycaemia in the presence of neuroglycopenic symptoms and documented Whipple's triad.
•Biochemically proven endogenous hyperinsulinemic hypoglycaemia (plasma glucose concentration <3.0 mM, insulin >3 µU/ml, and C-peptide >0.6 ng/ml).
•Conventional imaging within 1 month
•Signed written consent
•Age above 6 years (congenital hyperinsulinemic with the symptoms onset in school age is also the subject of this study)

Exclusion criteria

•Pregnancy
•Breastfeeding
•Renal function: serum creatinine > 3.0 mg/dl
•Known allergy against exendin-4
•Any medical condition that, in the opinion of the investigator, may significantly interfere with study compliance.

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK
1
Other (unclassified)
1

Safety / tolerability / PK

1 endpoint
Secondary/protocol endpoint

Adverse events collection

Time frame:1 week

Treatment-emergent AEs (any)

event count, event

Other (unclassified)

1 endpoint
Primary/protocol endpoint/low confidence

Standardized uptake value of 68Ga-NOTA-exendin-4 PET/CT in Diagnosis of Insulinoma and Nesidioblastosis

Time frame:1 year

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.